FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890837529> ?p ?o ?g. }

• W2890837529 endingPage "339" @default.
• W2890837529 startingPage "333" @default.
• W2890837529 abstract "Abstract Background Psoriasis in many patients is a chronic and recalcitrant disease that requires long‐term treatment, reinforcing the importance of long‐term safety data. Ixekizumab, a high‐affinity monoclonal antibody that selectively targets interleukin (IL)‐17A, is approved for treating patients with moderate‐to‐severe plaque psoriasis. Objective To determine long‐term safety of ixekizumab in psoriasis. Methods Integrated safety data are presented from 12‐week induction period, 12–60‐week maintenance period, and from all ixekizumab‐treated patients from 11 clinical studies. Exposure‐adjusted incidence rates (IRs) per 100 patient‐years are reported. Results Overall, 5689 patients accounted for 12 061.5 patient‐years of ixekizumab exposure from 11 studies. Over 156 weeks, a total of 83.9% ( n = 4775) of patients reported treatment‐emergent adverse events (AEs). Most opportunistic infections (IR [95% confidence interval; CI] 1.8 [1.6, 2.1]) reported were mucocutaneous candidiasis. The IR (95% CI) for oral Candida infection was 0.9 (0.8, 1.1). There was no trend of increase in IR of AEs of special interest. Serious AEs were reported in 11.8% of patients; death occurred in 0.4% ( n = 23) of patients. Conclusion The 3‐year, long‐term maintenance treatment with ixekizumab did not show any new safety signals in patients with moderate‐to‐severe plaque psoriasis." @default.
• W2890837529 created "2018-09-27" @default.
• W2890837529 creator A5000572878 @default.
• W2890837529 creator A5008217303 @default.
• W2890837529 creator A5016944101 @default.
• W2890837529 creator A5019891167 @default.
• W2890837529 creator A5059337854 @default.
• W2890837529 creator A5061849637 @default.
• W2890837529 creator A5063329929 @default.
• W2890837529 creator A5086273186 @default.
• W2890837529 date "2018-11-22" @default.
• W2890837529 modified "2023-09-25" @default.
• W2890837529 title "Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials" @default.
• W2890837529 cites W1549365041 @default.
• W2890837529 cites W1967720741 @default.
• W2890837529 cites W1979267587 @default.
• W2890837529 cites W1985813285 @default.
• W2890837529 cites W2004186675 @default.
• W2890837529 cites W2016080645 @default.
• W2890837529 cites W2016834798 @default.
• W2890837529 cites W2022665587 @default.
• W2890837529 cites W2055577285 @default.
• W2890837529 cites W2076116648 @default.
• W2890837529 cites W2082622860 @default.
• W2890837529 cites W2083707884 @default.
• W2890837529 cites W2107306178 @default.
• W2890837529 cites W2131430597 @default.
• W2890837529 cites W2168080197 @default.
• W2890837529 cites W2171889601 @default.
• W2890837529 cites W2296449002 @default.
• W2890837529 cites W2339525054 @default.
• W2890837529 cites W2418506270 @default.
• W2890837529 cites W2551958233 @default.
• W2890837529 cites W2562079198 @default.
• W2890837529 cites W2617690685 @default.
• W2890837529 cites W2620306249 @default.
• W2890837529 cites W2754104556 @default.
• W2890837529 doi "https://doi.org/10.1111/jdv.15242" @default.
• W2890837529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30198588" @default.
• W2890837529 hasPublicationYear "2018" @default.
• W2890837529 type Work @default.
• W2890837529 sameAs 2890837529 @default.
• W2890837529 citedByCount "48" @default.
• W2890837529 countsByYear W28908375292018 @default.
• W2890837529 countsByYear W28908375292019 @default.
• W2890837529 countsByYear W28908375292020 @default.
• W2890837529 countsByYear W28908375292021 @default.
• W2890837529 countsByYear W28908375292022 @default.
• W2890837529 countsByYear W28908375292023 @default.
• W2890837529 crossrefType "journal-article" @default.
• W2890837529 hasAuthorship W2890837529A5000572878 @default.
• W2890837529 hasAuthorship W2890837529A5008217303 @default.
• W2890837529 hasAuthorship W2890837529A5016944101 @default.
• W2890837529 hasAuthorship W2890837529A5019891167 @default.
• W2890837529 hasAuthorship W2890837529A5059337854 @default.
• W2890837529 hasAuthorship W2890837529A5061849637 @default.
• W2890837529 hasAuthorship W2890837529A5063329929 @default.
• W2890837529 hasAuthorship W2890837529A5086273186 @default.
• W2890837529 hasConcept C120665830 @default.
• W2890837529 hasConcept C121332964 @default.
• W2890837529 hasConcept C126322002 @default.
• W2890837529 hasConcept C156662089 @default.
• W2890837529 hasConcept C16005928 @default.
• W2890837529 hasConcept C197934379 @default.
• W2890837529 hasConcept C2776260265 @default.
• W2890837529 hasConcept C2779134260 @default.
• W2890837529 hasConcept C2779745271 @default.
• W2890837529 hasConcept C2779786854 @default.
• W2890837529 hasConcept C2780564577 @default.
• W2890837529 hasConcept C3020604521 @default.
• W2890837529 hasConcept C535046627 @default.
• W2890837529 hasConcept C61511704 @default.
• W2890837529 hasConcept C71924100 @default.
• W2890837529 hasConceptScore W2890837529C120665830 @default.
• W2890837529 hasConceptScore W2890837529C121332964 @default.
• W2890837529 hasConceptScore W2890837529C126322002 @default.
• W2890837529 hasConceptScore W2890837529C156662089 @default.
• W2890837529 hasConceptScore W2890837529C16005928 @default.
• W2890837529 hasConceptScore W2890837529C197934379 @default.
• W2890837529 hasConceptScore W2890837529C2776260265 @default.
• W2890837529 hasConceptScore W2890837529C2779134260 @default.
• W2890837529 hasConceptScore W2890837529C2779745271 @default.
• W2890837529 hasConceptScore W2890837529C2779786854 @default.
• W2890837529 hasConceptScore W2890837529C2780564577 @default.
• W2890837529 hasConceptScore W2890837529C3020604521 @default.
• W2890837529 hasConceptScore W2890837529C535046627 @default.
• W2890837529 hasConceptScore W2890837529C61511704 @default.
• W2890837529 hasConceptScore W2890837529C71924100 @default.
• W2890837529 hasFunder F4320307758 @default.
• W2890837529 hasIssue "2" @default.
• W2890837529 hasLocation W28908375291 @default.
• W2890837529 hasLocation W28908375292 @default.
• W2890837529 hasOpenAccess W2890837529 @default.
• W2890837529 hasPrimaryLocation W28908375291 @default.
• W2890837529 hasRelatedWork W2325746433 @default.
• W2890837529 hasRelatedWork W2904527393 @default.
• W2890837529 hasRelatedWork W3080588810 @default.
• W2890837529 hasRelatedWork W3119370474 @default.

• next